HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 364 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $74,987 | +11.5% | 1,963 | +5.3% | 0.01% | +14.3% |
| Q2 2023 | $67,271 | +13.1% | 1,865 | +19.8% | 0.01% | 0.0% |
| Q1 2023 | $59,462 | -45.2% | 1,557 | -18.3% | 0.01% | -46.2% |
| Q4 2022 | $108,451 | +23.2% | 1,906 | -14.8% | 0.01% | -13.3% |
| Q3 2022 | $88,000 | -8.3% | 2,237 | +2.1% | 0.02% | -6.2% |
| Q2 2022 | $96,000 | +10.3% | 2,191 | +0.6% | 0.02% | +23.1% |
| Q1 2022 | $87,000 | -34.1% | 2,178 | -33.8% | 0.01% | -35.0% |
| Q4 2021 | $132,000 | +6500.0% | 3,288 | +7546.5% | 0.02% | +1900.0% |
| Q3 2021 | $2,000 | 0.0% | 43 | 0.0% | 0.00% | – |
| Q2 2021 | $2,000 | 0.0% | 43 | 0.0% | 0.00% | – |
| Q1 2021 | $2,000 | 0.0% | 43 | 0.0% | 0.00% | – |
| Q4 2020 | $2,000 | +100.0% | 43 | 0.0% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 43 | -23.2% | 0.00% | – |
| Q1 2020 | $1,000 | -92.9% | 56 | -94.4% | 0.00% | -100.0% |
| Q4 2018 | $14,000 | – | 1,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |